Onconetix, Inc. (NASDAQ:ONCO - Get Free Report)'s share price dropped 24.9% during mid-day trading on Friday . The stock traded as low as $4.65 and last traded at $4.73. Approximately 302,077 shares traded hands during trading, an increase of 193% from the average daily volume of 102,989 shares. The stock had previously closed at $6.30.
Analyst Upgrades and Downgrades
Separately, Wall Street Zen upgraded shares of Onconetix to a "hold" rating in a report on Saturday.
Read Our Latest Stock Analysis on Onconetix
Onconetix Stock Performance
The stock's 50-day moving average is $6.05 and its 200-day moving average is $24.43.
Onconetix (NASDAQ:ONCO - Get Free Report) last issued its quarterly earnings results on Thursday, June 12th. The company reported $21.25 earnings per share for the quarter. Onconetix had a negative return on equity of 514.04% and a negative net margin of 2,913.71%. The company had revenue of $0.10 million for the quarter.
Institutional Trading of Onconetix
A hedge fund recently bought a new stake in Onconetix stock. Millennium Management LLC acquired a new position in shares of Onconetix, Inc. (NASDAQ:ONCO - Free Report) during the 4th quarter, according to its most recent filing with the SEC. The institutional investor acquired 39,477 shares of the company's stock, valued at approximately $25,000. Millennium Management LLC owned 0.48% of Onconetix at the end of the most recent reporting period. 23.89% of the stock is owned by institutional investors.
About Onconetix
(
Get Free Report)
Onconetix, Inc, a biotechnology company, focuses on the research, development, and commercialization of solutions for men's health and oncology. It offers Entadfi, an FDA-approved, once daily pill that combines finasteride and tadalafil for the treatment of benign prostatic hyperplasia; and Proclarix, an in vitro protein-based blood diagnostic test for prostate cancer.
See Also
Before you consider Onconetix, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Onconetix wasn't on the list.
While Onconetix currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are hedge funds and endowments buying in today's market? Enter your email address and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying now.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
